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Abstract
Background: According to the World Health Organization (WHO) there is a pandemic of obesity with approximately 300
million people being obese. Typically, human obesity has a polygenetic causation. Neutral endopeptidase (NEP), also known
as neprilysin, is considered to be one of the key enzymes in the metabolism of many active peptide hormones.
Methodology/Principal Findings: An incidental observation in NEP-deficient mice was a late-onset excessive gain in body
weight exclusively from a ubiquitous accumulation of fat tissue. In accord with polygenetic human obesity, mice were
characterized by deregulation of lipid metabolism, higher blood glucose levels, with impaired glucose tolerance. The key
role of NEP in determining body mass was confirmed by the use of the NEP inhibitor candoxatril in wild-type mice that
increased body weight due to increased food intake. This is a peripheral and not a central NEP action on the switch for
appetite control, since candoxatril cannot cross the blood-brain barrier. Furthermore, we demonstrated that inhibition of
NEP in mice with cachexia delayed rapid body weight loss. Thus, lack in NEP activity, genetically or pharmacologically, leads
to a gain in body fat.
Conclusions/Significance: In the present study, we have identified NEP to be a crucial player in the development of obesity.
NEP-deficient mice start to become obese under a normocaloric diet in an age of 6–7 months and thus are an ideal model
for the typical human late-onset obesity. Therefore, the described obesity model is an ideal tool for research on
development, molecular mechanisms, diagnosis, and therapy of the pandemic obesity.
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Introduction
Human obesity is a very serious health disorder that has a
polygenetic predisposition and is accompanied by dramatic
consecutive morbidities (e.g. hypertension, enhanced risk of
myocardial infarction, diabetes, and articular gout). In the last
decades, overweight [BMI 25–30] and obesity [BMI beyond 30]
has become an epidemic in industrial countries [1,2]. According to
UK statistics in 2006, 38% of adults were classified as overweight
and 24% were classified as obese. Even 30% of children from the
age of 2 to 15 were classified as overweight or obese. More than
5% of public health budgets in industrialized nations are spent on
the treatment of obesity [3]. However, medical treatment of
obesity to date has been disappointing with the greatest impact
being bariatric surgery. Consequently, there is a critical need for
new and innovative strategies to address the problem and
molecular targeting is the focus of intensive biomedical research.
Human obesity has a polygenetic causation [4]. In this context,
genetically modified animals, especially several knockout mice are
of greatest interest.
Recently, these knockout models have allowed the identification
of several singular molecular components for the development of
obesity [5], e.g. of leptin [6], insulin-(receptor) [7], interleukin-6
[8], GIP-(receptor) [9], pro-opiomelanocortin (POMC) and
derivatives [10]. These publications substantially expanded the
knowledge base on the molecular background of obesity.
However, all of these studies described monogenetic reasons for
the development of obesity. As mentioned above, the typical
inherited human obesity has a polygenetic basis. Therapeutic
approaches therefore need a target influencing multiple signaling
pathways or functions, e.g. transcription factors, second messen-
gers, or peptidases in order to reflect the polygenetic character of
obesity. Among the peptidases the membrane-bound (type-II)
metallo-enzyme neutral endopetidase (NEP or neprilysin,
E.C.3.4.24.11) is of increasing interest as it generates or catabolises
a large number of bioactive peptides and is widely distributed
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etc.) [11,12]. Promoted by the availability of specific inhibitors and
of knockout mice, many biochemical and physiological properties
of this peptidase have been described in detail. Typical substrates
are the enkephalines, NPY, CCK, bradykinin, angiotensin,
bombesin, ANP, the insulin chain, substance P [11], and the
‘‘Alzheimer-peptide’’ b-Amyloid (Ab) [13]. Importantly, among
the NEP substrates is a couple of important orexigenic and
anorexigenic compounds. The here presented results on the late-
onset obesity are based on the availability of NEP-knockout mice;
an animal model that plays also a crucial role in the discovery of
the molecular background of further metabolic diseases [14].
Results and Discussion
Using NEP-deficient mice and their wild-type controls for
pathophysiological and biochemical analysis [15–17], we observed
that mice with a genetic NEP deletion are characterized by a gain
in body weight that became obvious only in elderly animals of
both genders (Figure 1a). A first investigation of this effect
identified a significant accumulation of fat tissue that was not
restricted to abdominal fat (Figure 1b and c). Detailed recording
of body weight over one year identified significant weight
differences for both, females and males, beginning in an age of
approx. 7 months (Figure 1d and e) due to a continuation in
body weight gain while wild-types reached a weight plateau.
Extrapolated to the human, this time span in a mouse life
corresponds to an age of approx. 35 to 40 years when many people
become overweight. To investigate whether the gain in body
weight was associated with increased food intake, we measured
exemplarily in females the food intake at two different time points.
When the differences between both genotypes first occurred
(around the 7
th month) and in aged animals (.11 months), NEP-
deficient mice ate significantly more than their age-matched wild-
type controls (Figure 1f).
To further confirm that the weight gain in NEP-deficient mice is
due to fat accumulation we used repeated in vivo NMR analyses
during the timeNEP-deficientmice developed their obese phenotype.
Figure1. Age-related obesity in NEP-deficient mice. (a) Comparison of a NEP-knockout (NEP 2/2) mouse with an age-matched wild-type animal
(NEP +/+). (b) Steatosis of thorax and heart in a NEP-knockout mouse. (c) Abdominal fat accumulation in a NEP-deficient animal. Age-dependent
development of body weight in (d) females and (e) males. Data is presented as means 6 SEM. Where not shown, error bars lie within the dimensions of
the symbols. Average per group 22 mice. Genotype effects ***P,0.001 by two-way ANOVA. Significant differences at specific times are calculated by
Bonferroni post-hoc test, **P,0.01 and ***P,0.001. (f) Daily food consumption in 7 and .11 month-old female NEP-knockout (NEP 2/2)
mice compared with age-matched wild-type animal (NEP +/+), *P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0012793.g001
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NEP knockouts (Figures 2a and b), whilst there was significant fat
accumulation (Figure 2c and d). Notably, the increase in fat mass
was comparable to the observed body weight gain. Investigations in
both aged genotypes in a respiration chamber could not identify
differences in their respiratory quotient (RQ-values wild-type:
0.74360.006 versus knockout: 0.73160.017) as well as in the
emitted body temperature related energy (wild-type: 0.47160.016
versus knockout: 0.47660 . 0 4 9k c a l / h ) .F u r t h e r m o r e ,t h eg a i ni n
body weight was also not associated with a lower locomotor activity as
measured by radio-telemetry (data not shown).
To investigate whether the obese phenotype was modifiable by
different food compositions, we fed females of both genotypes with
either a low- or a high-fat diet (Mean food consumptions [in g/
animal/d]; for low fat diet: wild-type: 3.360.4 versus knockout:
3.960.2; for high fat diet: wild-type: 3.060.1 versus knockout:
3.760.4). As shown in Figure 2e, the phenotype was much more
pronounced under low fat diet, while high fat diet almost blunted
the body weight differences due to a massive rise in body weight of
wild-type mice (Figure 2f).
Obesity is often associated with a deregulation in non-complex
lipid metabolism. As described for human obese people [18], our
overweight NEP-deficient animals in an age of 12 months where
characterized by higher concentration of serum triglycerides under
normal food diet (Figure 3a) in comparison to their age-matched
wild-type controls. Also fitting to the human situation, the analysis
of cholesterol sub-fractions uncovered an unequal regulation.
While the ‘‘good’’ HDL was significantly lowered (Figure 3b,
left panel), the concentration of VLDL, a risk marker for
cardiovascular diseases [18,19], was significantly increased
(Figure 3b, right panel).
Since it has been shown that leptin is a key molecule in the
development of an obese phenotype [20], we investigated the role
of this anorexigenic peptide hormone in the NEP knockout-
mediated weight gain by measuring circulating leptin concentra-
tion in our animal model. As described for wild-type animals
before, increasing leptin levels in NEP-deficient mice correlated
with increasing body weight [9,21] (Figure 3c). This normal
regulation excludes a deficiency in leptin generation by fat tissue
and therefore a reduced leptin-mediated control of food intake as
being responsible for the fat accumulation in our NEP-deficient
mice.
Since obesity is associated with a variety of secondary
pathologies as diabetes mellitus type 2, we investigated whether
obese NEP-deficient mice had alterations in glucose homeostasis
and metabolism. Fasting blood glucose levels under basal
conditions were significantly elevated in one-year old NEP-
deficient mice (Figure 3d). Moreover, a glucose tolerance test
revealed that these animals showed a significant weaker ability to
handle an oral glucose load (Figure 3e). A similar trend between
Figure 2. Body composition and diet-depending weight development in NEP-deficient mice. NMR-monitored influence of feeding on
age-dependent body composition in mice fed with low fat diet divided in (a) muscle masses, (b) free body fluid, (c) fat masses, and (d) fat masses per
body weight. Effects of (e) low fat and (f) high fat diet on the development of body mass. Data is presented as means 6 SEM of at least 10 animals
per group. Two-way ANOVA **P,0.01; ***P,0.001. Where not shown, error bars lie within the dimensions of the symbols. Genotype effects are
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young animals.
The lack of compensation for the loss of NEP by functionally
and structurally related peptidases (APN, ACE) in the untreated
animals shows that NEP-deficient mice and their corresponding
wild-type strain constitute an excellent animal model to charac-
terize NEP-related processes [16,22,23]. However, a classical
argument against data generated in knockout models is the
modification of a variety of other gene products regulated
secondarily to the life-long-gene deficiency, but being responsible
for the described phenotype. Thus, we investigated, whether the
obese phenotype in NEP-deficient mice could also be generated by
a more acute pharmacological inhibition of that peptidase. There
is data suggesting an effect of nonspecific NEP inhibition on food
intake in sheep [24]; therefore we treated 6-month-old wild-type
mice with the specific NEP inhibitor candoxatril (UK 79,300)
given as a food additive [25]. Already after 20 days treatment,
mice gained significantly more weight than sham-treated animals,
and continued to do so over 40 days (Figure 4a). In accord with
the results for the NEP-deficient mice due to genetic manipulation,
the gain in weight mediated by candoxatril treatment was caused
by a fat accumulation (Figure 4b). To answer the question
whether the observed NEP-dependent fat accumulation is caused
by stimulation of food intake or better food utilization, we
recorded the daily food intake under candoxatril treatment. The
data shown in Figure 4c clearly illustrate that the weight gain was
caused by a significant increase in food consumption. Importantly,
this orexigenic effect of candoxatril was already observed within
the first measurements and thus supports the conclusion of NEP
inhibition being primarily responsible for changes in peptide
hormone concentrations that led to the observed stimulation in
food intake.
In addition to its specificity, a second advantage of candoxatril is
that it is thought not to pass through the blood brain barrier, thus
discriminating between peripheral and central NEP effects on
body weight. To check for candoxatril’s ability to inhibit central
NEP activity, we measured the peptidase’s capacity to generate a
NEP-specific degradation product in organs after application of
Figure 3. Biochemical parameters in obese NEP-deficient mice under low fat diet. (a) Serum triglycerides in one-year old NEP-deficient
animals (2/2) and their age-matched wild-type controls (+/+). Student’s t-test ***P,0.001 versus wild-type. (b) Serum HDL (left panel) and VLDL
(right panel) in both genotypes. Data is presented as means 6 SEM. Student’s t-test ***P,0.001 versus wild-type. (c) Significant correlation of serum
leptin levels in NEP-deficient mice with increasing body weight (r
2 0.92 [Pearson correlation]). (d) Comparison of basic glucose values (before glucose
tolerance test) in plasma of NEP-knockout mice with wild-type animals. Student’s t-test **P,0.01 versus wild-type. (e) Comparison of NEP-knockout




PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12793different doses of candoxatril in vivo for 14 days. Neither a low nor
a high dose of the NEP inhibitor had an effect on NEP activity in
the brain cortex (Figure 4d, right panel). In contrast,
peripheral NEP, as exemplarily shown for the kidney as one of
the organs with highest NEP expression, was already significantly
inhibited using the lower candoxatril concentration (Figure 4d,
left panel).
All data shown here demonstrate a significant effect of lower
NEP activity (either by pharmacological inhibition or genetic
manipulation) on fat accumulation and thus pathological gain in
body weight. However, there are pathophysiological circumstanc-
es such as tumor cachexia, where a rapid loss in weight would
make stimulation in food intake a therapeutic option. The
potential NEP inhibition of tumor-induced weight loss was
investigated by use of candoxatril in nude mice bearing the
human PSN-1 pancreatic carcinoma. This tumor type leads to a
severe tumor cachexia very similar to the clinical situation. Tumor
cachexia started 12 days after tumor implantation and achieved a
maximum at the endpoint of the experiment, at day 23 after tumor
inoculation (tumor weight loss .30% between day 12 and day 23).
Treatment with candoxatril starting day 9 after tumor inoculation
led to a significantly less pronounced loss in body weight compared
with control-treated mice (Figure 4e). The growth of the primary
tumor and the weight of liver, spleen and kidney at day 23 after
tumor implantation were not affected by NEP inhibition.
There is a critical need for novel treatment strategies for obesity,
particularly as current oral medical treatment has had little
impact. Molecular targeting may be one such approach. We have
identified NEP to play a crucial role in food intake and in fat
accumulation. Since the development of obesity in NEP-deficient
mice starts at 6–7 months, this is an ideal model for typical human
late-onset obesity. In contrast to the wide number of single genes
Figure 4. Effects of candoxatril (Pfizer, UK79,300) on body mass development. (a) Development of body weight in male C57BL/6 mice
starting in an age of 6 months fed with standard diet, supplemented with placebo (solid line and squares) or of the NEP inhibitor candoxatril
[consumption 200 mg/kg/day] (broken line and triangles). Treatment day 0 is the first day of treatment. Treatment effect ***P,0.001 by two-way
ANOVA. Significant differences at specific time-points are calculated by Bonferroni post-hoc test, *P,0.05 and **P,0.01. (b) Abdominal fat in male
C57BL/6 mice after feeding with standard food (open column) or with food supplemented with the NEP inhibitor candoxatril (black column) for two
months [consumption 200 mg/kg/day]. Student’s t-test **P,0.01 versus placebo. (c) Development of food intake in male C57BL/6 mice fed with
standard food (open columns) or the same food supplemented with the NEP inhibitor candoxatril (black columns) [consumption 200 mg/kg/day].
Student’s t-test **P,0.01, ***P,0.001 versus placebo. (d) Development of NEP activity in kidney (left panel) and brain (right panel) of mice after oral
treatment with candoxatril (1) Placebo, (2) 100 mg/kg/day candoxatril, (3) 200 mg/kg/day candoxatril. Student’s t-test *P,0.05, **P,0.01 versus
placebo. (e) Development of body weight in male tumor-bearing mice (Pancreas carcinoma, PSN-1) fed with standard food (solid line and squares) or
standard food supplemented with the NEP inhibitor candoxatril (200 mg/kg/day, broken line and triangles). Treatment effect *P,0.05, by two-way
ANOVA. Significant differences at specific time-points are calculated by Bonferroni post-hoc test, *P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0012793.g004
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phenotype, NEP fulfils the criteria for being a classical target in
obesity with a polygenetic causation. This metallopeptidase
hydrolyzes a large number of peptide hormones and is widely
distributed throughout the body.
In contrast to other obesity models, our animals develop an
obese phenotype under normocaloric conditions. Interestingly,
with a high fat diet the significant difference between both
genotypes declines, because the wild-type mice also become obese.
This makes the NEP-deficient animals an even more relevant
obesity model, since it reflects a classical situation where middle-
aged people consuming food of normal (even healthy) quality
become overweight whilst their diet remains unchanged. In
addition, NEP-deficient animals develop lipid and glucose
abnormalities, akin to type 2 diabetes, as the obesity develops [26].
A strong argument supporting NEP to be centered in food
intake control is data of a reversal experiment. If reduction of NEP
activity leads to stimulation in food intake, its pharmacological
inhibition should prevent a massive reduction in body weight in a
model of pathological body weight loss. We could demonstrate in
mice bearing a pancreas carcinoma PSN-1 that specific NEP
inhibition significantly reduces the loss in body weight until the
experiment was stopped. Although the psychological impact in
diseases like anorexia nervosa might be the dominant one, further
experiments should evaluate whether the inhibition of NEP or
signaling of NEP-targeted orexigens can reduce the body weight
loss in diseases with pathological reduction in body weight.
As described above, NEP activity has massive impact on body
mass and fat accumulation. The molecular background of this
effect is hitherto not fully clarified, and a detailed description of the
underlying mechanisms requires extensive research. On the other
hand, on the basis of today’s knowledge it might be predicted that
the NEP-evoked degradation of substrates with pronounced
orexigenic properties, such as NPY, galanin, or CNP should play
an important role [27–29]. Own results and multiple references
characterize these peptide hormones as proper substrates for
mammalian NEP [11,30,31]. Thus, a deletion or a specific
pharmacological inhibition of NEP may accumulate such orexi-
gens and consequently lead to stimulated food intake and fat
accumulation. The fact that the inhibition of peripheral NEP
activity leads to the observed phenotype further reduces the
number of candidate peptides. That the central NEP may not be
important in appetite control makes the peptidase a promising
pharmacological target, since it is not required that an inhibitor
crosses the blood-brain barrier. This prevents alterations in
complex central control mechanisms of behavior and emotional
status. Over the last years, the model of a gut-brain axis has been
developed [32]. That peripheral rather than central NEP is crucial
for food intake and fat accumulation fits this model. NEP targets,
which peripherally accumulate when NEP activity declines may
signal to the brain and thus lead to an orexigenic stimulus.
Since the pharmacological increase in NEP might be difficult,
the identification of orexigenic peptides (and their receptors)
influenced by NEP activity may be a promising targeted approach
to reduce body weight for the treatment of obesity.
Materials and Methods
Animals
We used male and female NEP-knockout mice that were
originally generated by Lu et al. [33] and maintained in the
breeding stocks of T.W. at the Charite ´, Campus Benjamin
Franklin (CBF), Berlin, Germany. Experimental animals were
bred from parents, which were F2 after hemizygous mating and
being on a C57Bl/6N background. Animals were housed in litters
separated according to sex at 2261uC in a 12 h/12 h light/dark
cycle with unrestricted access to food and water. Recordings of
physiological parameters were performed between 9:00 a.m. and
1:00 p.m.
Experiments on adult mice were performed in accordance with
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85–
23, revised 1996), the regulations of the Animal Care Committee
of the Erasmus MC, and the Federal Law on the Use of
Experimental Animals in Germany, and were approved by the
local authorities (Landesamt fu ¨r Gesundheit und Soziales des
Landes Berlin).
Diets
All animals obtained normal water al libitum and the following
sorts of food:
Food I: Standard food; ‘‘ssniff SM/R/N-H (10 mm)’’, (calorific
value: 12.2 MJ/kg) ssniff Spezialdia ¨ten GmbH, Soest, Germany,
used for experiments described in Figure 1 and Figure 4.
Food II: (‘‘Low fat diet’’): ‘‘Altromin Standard-1324’’; Altromin
(calorific value: 12.5 MJ/kg; in this diet 13.6% of the convertible
energy is attributed to the fat content), used for experiments
described in Figure 2a–e.
Food III: (‘‘High fat diet’’): ‘‘Altromin C1057’’ (calorific value:
14.6 MJ/kg; in this diet 35.0% of the convertible energy is
attributed to the fat content), used for experiments described in
Figure 2f.
Food IV: Standard food (see above Food I) was cold milled,
supplemented with the frequently used, well tolerated, orally active
and tasteless NEP-inhibitor candoxatril (Pfizer) [34,35], mixed and
grouted under pressure (2 g/kg); this corresponds to a daily
consumption of approx. 200 mg/kg/day. The manufacturing of
candoxatril-containing food was performed as usually by the
producer (ssniff/Germany). The used control food was prepared at
the same day by the same management; used for experiments
described in Figure 4.
NMR analytics
Body composition was measured by NMR spectroscopy
(Minispec MQ10 NMR Analyzer [Bruker, Billerica, Massachu-
setts/USA; www.minispec.com] in female mice using software by
Echo Medical Systems [Houston, Texas, USA]).
Respiration chamber and indirect calorymetry
Energy expenditure and metabolic fuel oxidation were estimat-
ed from oxygen consumption, carbon dioxide production, and
urinary nitrogen excretion in open circuit metabolic cages as
described previously by Aust et al. [36]. Oxygen concentration in
the air was measured paramagnetically and carbon dioxide
concentration by infrared absorption. From these values the
respiratory quotient (RQ) was calculated. The parameters were
controlled by the equipment of Braun & Hartmann (Minden,
Germany) and stored online for each cage (mouse): Air flow; basic
value for mice: 30 Nl/h performed by an air compressor; Actual
O2 content (vol%); Actual CO2 production (ppm); Actual air
pressure (hPa).
The indirect calorymetry was performed with single-housed
mice in their home cages having a solid hermetically sealed lid.
Biochemical analyses
Serum leptin levels were measured by ELISA (mouse leptin
immunoassay kit Quantikine, MOB00, R&D Systems Inc.,
NEP and Obesity
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LDX equipment (Cholesttech Corp., Hayward, CA, USA)
according to the producer’s manuals. All animals were in an age
of 12 months.
Glucose tolerance test
Eight female and 9 male wild-type as well as 10 female and 9
male NEP-knockout mice in an age of 12 months were tested for
oral glucose tolerance. Basal blood glucose levels after 8 hour
fasting were tested prior to the test (starting 8am). After oral
application of a glucose solution (1 mg/g body weight) blood
glucose levels were recorded after 30 min, 60 min, 90 min, and
120 min. The investigator was blinded to the genotypes.
Measurement of NEP activity
NEP activity was measured according to Winkler et al. [37]
using high performance liquid chromatography (HPLC) to
monitor [D-Ala2, Leu5]enkephalin (DALEK, 100 mM) degrada-
tion and the parallel formation of Tyr–D-Ala–Gly in the presence
of the aminopeptidase inhibitor bestatin (10
24 M) and the
angiotensin-converting enzyme inhibitor lisinopril (10
26 M). The
specificity of the reaction was characterised using 10
25 M
candoxatrilat (Pfizer, UK73,967). Neutral endopeptidase activity
was measured twice in all samples.
Cachexia
Male NMRI:nu/nu mice aging 6 months (n=16) were
subcutaneously implanted with the human PSN-1 pancreatic
carcinoma and equally allocated to a control (standard food) and
treatment group (standard food + candoxatril; Food IV). Growth
of the subcutaneous tumor and weight of the animals were daily
monitored. Treatment was started on day 1 after tumor
inoculation. Treatment was continuously performed until day 23
after tumor implantation (end of the experiment) whereby the
researcher was blinded to the experimental groups. Weight of the
liver, spleen, kidney and tumor was measured at the end of the
experiment.
Radio-telemetry experiment
Seven NEP-deficient mice and 7 age-matched wild-type
controls received a telemetry implant (TA11-PA20; Data Sciences
International, St Paul, Minnesota, USA) in the carotid artery as
described earlier by Gross et al. [38]. In brief, the zero offset of the
instrument was measured and the unit was soaked in 0.9% NaCl
before implantation. Animals were anaesthetized with a mixture of
ketamine (10 mg/kg) and xylasine (5 mg/kg). The transmitter
catheter was inserted into the aortic arch via the left carotid artery.
Thereafter, the catheter was sealed in place. After careful
replacement of the intestine, the body of the transmitter was fixed
on the abdominal wall and the cavity was closed with sutures. All
mice were housed in individual cages in a sound-attenuated room.
Beginning one week after surgery, the animals were monitored for
3 days receiving control diet.
Data analyses
Data were analyzed by Student’s t test or ANOVA with
repeated measures, as appropriate.
Significant interactions identified by ANOVA were analyzed
using a Bonferroni post-hoc test for pair wise comparisons.
Statistical calculations were performed using Prism or Instat
software from GraphPad, San Diego (USA). P,0.05 values were
considered to be statistically significant.
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